GRAd-COV2

Cepheid Receives CE Mark for Xpert® Xpress CoV-2 plus

Retrieved on: 
Thursday, May 19, 2022
Severe acute respiratory syndrome coronavirus 2, Test, Virus, Infection, Solution, COVID-19, Marketing, Molecular biology, Genetic drift, EVP, GRAd-COV2, Mutation, Cancer, Xpress, Vaccine, Heating, ventilation, and air conditioning, Pharmaceutical industry, Cepheid variable

SUNNYVALE, Calif., May 19, 2022 /PRNewswire/ -- Cepheid today announced it has received the CE mark for Xpert®Xpress CoV-2 plus, a rapid molecular diagnostic test for qualitative detection of the virus that causes COVID-19.

Key Points: 
  • Cepheid is proactively addressing this increasing genetic diversity by enhancing gene coverage.
  • Xpert Xpress CoV-2 plus joins XpertXpress CoV-2/Flu/RSV plus and others in Cepheid's growing portfolio of PCRplus respiratory tests that deliver rapid, accurate, and actionable respiratory results.
  • Xpert Xpress CoV-2 plusis designed for use on any ofCepheid'sover 40,000 GeneXpertsystems placed worldwide.
  • Xpert Xpress CoV-2 plus is expected to begin shipping in May.

Cepheid Receives Emergency Use Authorization for Xpert® Xpress CoV-2 plus

Retrieved on: 
Thursday, May 12, 2022
Severe acute respiratory syndrome coronavirus 2, Test, EUA, Federal Food, Drug, and Cosmetic Act, Virus, Infection, Solution, COVID-19, Marketing, FDA, Molecular biology, Genetic drift, EVP, GRAd-COV2, Mutation, Cancer, Diagnosis, Laboratory, Xpress, Pharmaceutical industry, Vaccine, Cepheid variable

SUNNYVALE, Calif., May 12, 2022 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert®Xpress CoV-2 plus, a rapid molecular diagnostic test for qualitative detection of the virus that causes COVID-19.

Key Points: 
  • Cepheid is proactively addressing this increasing genetic diversity by enhancing gene coverage.
  • Xpert Xpress CoV-2 plus joins XpertXpress CoV-2/Flu/RSV plus and others in Cepheid's growing portfolio of PCRplus respiratory tests that deliver rapid, accurate, and actionable respiratory results.
  • Xpert Xpress CoV-2 plus is expected to begin shipping to US customers in May.
  • Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.

Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform

Retrieved on: 
Tuesday, July 6, 2021
Medicine, Medical specialties, Health, Adenoviridae, Virology, Vaccine, Virus, GRAd-COV2, Oncolytic adenovirus

OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.

Key Points: 
  • OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
  • The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19.
  • The single-cycle adenovirus platform was developed to enhance the expression of target antigens, amplifying immune responses to infectious disease targets.
  • Preclinical studies have demonstrated that the single-cycle adenovirus can markedly increase target antigen expression over that of currently utilized replication defective adenovirus vaccines.